News :: Fresh Tracks Therapeutics, Inc. (FRTX)

Contact Us

Jul 22, 2021 4:05pm EDT

Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter’s Option to Purchase Additional Shares

Jul 19, 2021 10:44pm EDT

Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million

Jul 19, 2021 5:25pm EDT

Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock

Jul 06, 2021 8:00am EDT

Brickell Biotech to Participate at William Blair’s Biotech Focus Conference 2021

Jun 29, 2021 4:05pm EDT

Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Jun 24, 2021 8:00am EDT

Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan

Jun 01, 2021 8:00am EDT

Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

May 13, 2021 4:01pm EDT

Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update

Apr 29, 2021 8:00am EDT

Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021

Apr 27, 2021 7:30am EDT

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis